Scopolamine does not restore normal conditioned avoidance performance in raclopride-treated rats

Journal of Neural Transmission

Volumn 108, Issue 4, 2001, Pages 415-430

  Ahlenius, S ^a   Ericson, E ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Antipsychotics; Conditioned avoidance; Raclopride; Rats; Scopolamine; Visual discrimination

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPAMINE 2 RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; RACLOPRIDE; SCOPOLAMINE;

ANIMAL EXPERIMENT; ARTICLE; AVOIDANCE BEHAVIOR; CATALEPSY; CONDITIONED REFLEX; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DRUG EFFECT; MALE; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PRIORITY JOURNAL; RAT; TASK PERFORMANCE; VISUAL DISCRIMINATION;

ANIMALS; ANTIPSYCHOTIC AGENTS; AVOIDANCE LEARNING; CONDITIONING (PSYCHOLOGY); DISCRIMINATION LEARNING; DRUG INTERACTIONS; MALE; MUSCARINIC ANTAGONISTS; NEOSTRIATUM; PARKINSON DISEASE; PHOTIC STIMULATION; RACLOPRIDE; RATS; RATS, SPRAGUE-DAWLEY; SCHIZOPHRENIA; SCOPOLAMINE;

EID: 0034901269     PISSN: 03009564     EISSN: None     Source Type: Journal    
DOI: 10.1007/s007020170063     Document Type: Article

References (66)

1. Inhibition of catecholamine synthesis and conditioned avoidance acquisition
2. Effects of low and high doses of L-DOPA on the tetrabenazine or α-methyltyrosine-induced suppression of the behavior in a successive discrimination task
3. Pharmacological evaluation of new antipsychotic drugs
4. Effects of apomorphine and haloperidol on exploratory behavior and latent learning in mice
5. Specific effects by the psychotomimetic drugs d-amphetamine and phencyclidine on the performance of an aversely motivated successive visual discrimination in the rat
6. Dopamine turnover in the corpus striatum and the limbic system after treatment with neuroleptic and antiacetylcholine drugs
7. Effect of local application of apomorphine to the corpus striatum and to the nucleus accumbens on the reserpine-induced rigidity in rats
8. Pharmacological specificity of conditioned avoidance response inhibition in rats: Inhibition by neuroleptics and correlation to dopamine receptor blockade
9. Further studies on the mechanism behind scopolamine-induced reversal of antistereotypic and cataleptogenic effects of neuroleptics in rats
10. The use of conditioned suppression to evaluate the nature of neuroleptic-induced avoidance deficits
11. Parallels between neuroleptic effects and lethargic encephalitis: The production of dyskinesias and cognitive disorders
12. Comparative behavioral and neurochemical activities of cholinergic antagonists in rats
13. Dementia in Parkinson's disease: Possible specific involvement of the frontal lobes
14. Motor and mental aspects of acute extrapyramidal syndromes
15. Catalepsy induced by striatal acetylcholinesterase inhibition with fasciculin in rats
16. Effects of classical and novel agents in a MPTP-induced reversible model of Parkinson's disease
17. Prediction of clinical effects of psychotropic drugs from animal data
18. Effects of drugs on behavior
19. Catalepsy and circling behaviour after intracerebral injections of neuroleptic, cholinergic and anticholinergic agents into the caudate-putamamen, globus pallidus and substantia nigra of rat brain
20. Schizophrenia-like psychoses associated with organic disorders of the central nervous system
21. Action of apomorphine, bromocriptine and lergotrile on GABA and acetylcholine release in nucleus accumbens and corpus striatum
22. Pathophysiology of Parkinson's signs
23. Modulatory functions of neurotransmitters in the striatum: ACh-dopamine-NMDA interactions
24. Central cholinergic systems and cognition
25. Haloperidol-induced disruption of conditioned avoidance responding: Attenuation by prior training or by anticholinergic drugs
26. Behavioral pharmacology and biochemistry of central cholinergic neurotransmission
27. Alterations of dopaminergic and noradrenergic innervations in motor cortex in Parkinson's disease
28. Animal models of Parkinson's disease: An empirical comparison with the phenomenology of the disease in man
29. Psychopharmacological effects of reversible cholinesterase inhibition induced by N-methyl-3-isopropyl phenyl carbamate (compound 10854)
30. Antagonism of the antiavoidance effects of various agents by anticholinergic drugs
31. 2 dopamine and N-methyl-D-aspartate receptor activation in rat nucleus accumbens and neostriatum
32. Effects of raclopride on exploratory locomotor activity, treadmill locomotion, conditioned avoidance behaviour and catalepsy in rats: Behavioural profile comparisons between raclopride, haloperidol and preclamol
33. The effect of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: A review and meta-analysis
34. Psychomotor impairment and cognitive disturbances induced by neuroleptics
35. Evidence for a cholinergic role in haloperidol-induced catalepsy
36. Catalepsy after microinjection of haloperidol into the rat medial prefrontal cortex
37. 2 receptors in the rat brain
38. Neuroleptic-like disruption of the conditioned avoidance response requires destruction of both the mesolimbic and nigrostriatal dopamine systems
39. 2 antagonists on decision making by rats: No reversal of neuroleptic-induced attenuation by scopolamine
40. The influence of anterior neostriatal lesions on the behavioural effects of spiroperidol in rats
41. A neurochemical and behavioral investigation of the involvement of nucleus accumbens dopamine in instrumental avoidance
42. Intracerebral haloperidol potentiates the dorsal immobility response in the rat
43. Differential antagonism of antiavoidance, cataleptic and ptotic effects of neuroleptics by biperiden
44. 2 dopamine receptors in neuroleptic catalepsy
45. Effects of scopolamine on delayed-matching-to-sample and paired associates tests of visual memory and learning in human subjects: Comparison with diazepam and implications for dementia
46. Effects of physostigmine on rat brain acetylcholine, acetylcholinesterase and conditioned pole jumping
47. Behavior and the basal ganglia
48. Differential attenuation of some effects of haloperidol in rats given scopolamine
49. Muscarinic receptor agonists, like dopamine receptor antagonist antipsychotics, inhibit conditioned avoidance response in rats
50. Treatment of extrapyramidal side effects
51. Intellectual changes in patients with MPTP-induced parkinsonism
52. Regulation of the activity of striatal cholinergic neurons by dopamine
53. Frontal lobe dysfunction in Parkinson's disease. The cortical focus of neostriatal outflow
54. Regional distribution of monoamine vesicular uptake sites in the mesencephalon of control subjects and patients with Parkinson's disease: A postmortem study using tritiated tetrabenazine
55. Dopaminergic and cholinergic interaction in cataleptic responses in mice
56. The conditioned avoidance response test reevaluated: Is it a sensitive test for the detection of potentially atypical antipsychotics?
57. Suppression of conditioned avoidance behavior by the local application of (-)sulpiride into the ventral, but not the dorsal, striatum of the rat
58. Potency mismatch for behavioral and biochemical effects by dopamine receptor antagonists: Implications for the mechanism of action of clozapine
59. 2 receptor antagonist raclopride in rats
60. Animal models in schizophrenia
61. Heterogeneity of melanized neurons expressing neurotensin receptor messenger RNA in the substantia nigra and the nucleus paranigralis of control and Parkinson's disease brain
62. Distinct sites of dopaminergic and glutamatergic regulation of haloperidol-induced catalepsy within the rat caudate-putamen